Senior Scientist I, Clinical Biomarker Development

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified

Salary

$149K-$186K not verified - source not recorded; timestamp not recorded

401(k) match

Not verified

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$111,944 U.S. median for this role

Projected growth (BLS Employment Projections)

+13.7% - Much faster than average

50% above the BLS role benchmark for data and ml aggregate.

Matched to SOC 15-1252 - Data and ML aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Schedule

Shift type

Not verified

Weekend work

Not verified

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Senior Scientist I, Clinical Biomarker Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Scientist I in Clinical Biomarker Development team, within the Translational Medicine will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicine's oncology pipeline. You will: - Design and execute clinical biomarker strategies to support early response monitoring, patient stratification, and understanding resistance mechanisms. - Support biomarker implementation for early- and late-stage oncology clinical trials. - Oversee biomarker assay development, qualification, and sample analysis in collaboration with internal teams and external CROs. - Analyze and interpret biomarker data in the context of clinical outcomes and present results to cross-functional teams. - Contribute to clinical protocols, study reports, and regulatory documents (e.g., INDs, IBs, CSRs). - Translate preclinical findings into clinically actionable biomarker hypotheses. - Stay current with emerging biomarker technologies and trends in precision oncology. Required Skills, Experience and Education: - PhD

Read the full description at www.revmed.com. FewerJobs shows a source-linked preview and links to the original posting.